Coronary Artery Disease
Conditions
Brief summary
The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary atherosclerosis.
Detailed description
The MARKOV study is an investigator-initiated, open-label, single arm, international, multicenter, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary atherosclerosis. The study will be conducted in 5 sites in 3 different countries in Europe. Patients will receive evolocumab for approximately 3 year. The expected duration of the entire study from First Subject First Visit to Last Subject Last Follow-up is 46 months (3 year and 10 months).
Interventions
BIOLOGICALEvolocumab
Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
Sponsors
Amgen
GE Healthcare
HeartFlow, Inc.
ECRI bv
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. At least 2 coronary vessels suitable for CCTA; vessels fulfilling all requirements below: a. patent main branch b. no previous stent placement 2. At least two of the evaluable vessels with subclinical coronary artery disease as defined non-invasively by CCTA with encroachment of the vessel and either: a. Lesion with visual diameter stenosis (DS) \< 50% or, b. Lesion with visual DS ≥ 50% and FFRCT \> 0.80; 3. No planned coronary revascularization (during the course of the study) at the time of enrollment; 4. Most recent, taken within 30 days prior to informed consent form (ICF) signature, fasting LDL-C ≥ 80 mg/dL (≥ 2.07 mmol/L) and on stable statin therapy for at least 30 days at the time of blood sampling, or statin-intolerant or for whom a statin is contraindicated. 5. Subject signed informed consent form
Exclusion criteria
1. History of coronary artery bypass surgery, heart transplantation, surgical or percutaneous valve repair and/or replacement 2. New York Heart Association (NYHA) class III or IV heart failure 3. Last known left ventricular ejection fraction \<30% 4. Active liver disease or hepatic dysfunction, either known or defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the upper limit of normal (ULN) 5. Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 6. Active malignancy except for adequately treated non-melanoma skin cancer or other non-invasive or in situ neoplasm (e.g. successfully treated cervical cancer in situ or non-active prostate cancer) Imaging CCTA-related 7. Absence of baseline CCTA obtained in the context of standard clinical care 8. Baseline CCTA not meeting Core Lab quality standards 9. Any contraindication for repeat CCTA such as known anaphylactic allergy to iodinated contrast Concomitant and study medication 10. Any prior or current use of PCSK9 inhibition treatment or any other experimental lipid-related drug Other
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in normalized area under the curve of fractional flow reserve derived from coronary computed tomography(CCTA) (FFRCT) at 18 months from baseline | 18 months of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in normalized area under the curve of fractional flow reserve derived from coronary computed tomography (FFRCT) at 36 months from baseline. | 36 months of treatment |
| Percent change of total atheroma burden (TAB) and changes in plaque composition at 18 and 36 months measured by Hounsfield unit of plaque with positive remodeling (>1.10) assessed by coronary computed tomography. | 18 and 36 months of treatment |
| Change and percent change after 18 and 36 months from baseline of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), lipoprotein (a), triglycerides, apolipoprotein A1 and B. | 18 and 36 months of treatment |
| Number of treatment emergent adverse events (TEAEs) and adverse events (AEs) of special interest (i.e. acute kidney injury, pregnancy and lactation) | 36 months of treatment |
| Incidence of all-cause death and the composite of Cardiovascular death, myocardial infarction, stroke, or coronary revascularization. The composite of Cardiovascular death, Myocardial infarction, or stroke | 36 months of treatment |
Outcome results
None listed